RxDoctor Payments Data

Susan Lee

Optometrist · Greensboro, GANPI 1801956503

Payments from drug & device makers

$1,389in general payments, 2019–2025

Across 32 payments — averaging $43.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coopervision Inc.$595
  • Bausch & Lomb Americas Inc.$285
  • Alcon$221
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$163
  • AbbVie$60
  • Oyster Point Pharma, Inc.$25
  • plus $41 from 2 others

What the payments were for

  • Speaking & faculty fees$33324%
  • Food & beverage$1,05676%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,389 in reported general payments places this provider in the 60th percentile of 1,285 optometrist providers in Georgia.

See all optometrist providers in Georgia

Medicare billing

Part B allowed, 2024
$174,524
Medicare patients
846
Services billed
2,263

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine34$29,774
Brimonidine Tartrate40$11,094
LumiganBimatoprost22$10,041
CombiganBrimonidine Tartrate/Timolol18$7,736
Latanoprost300$5,444
Travoprost16$4,583
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol24$4,036
Travatan ZTravoprost11$2,737
Prednisolone Acetate64$2,011
Timolol Maleate89$981
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat45$890
Tobramycin-DexamethasoneTobramycin/Dexamethasone28$815
ValacyclovirValacyclovir Hcl26$581
Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim16$107
Triamcinolone Acetonide26$52

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$60$47,55174 claims
NovartisTravatan Z$21$2,73711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,285 optometrist providers in Georgia.

Other optometrist in Greensboro

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →